Despite recent earnings drop, the company's P/E ratio aligns with most firms, indicating investors might be ignoring limited growth rates and are ready to pay for stock exposure. This could lead to future disappointment if P/E falls to levels matching recent growth rates.
Jilin Jian Yisheng Pharmaceuticalに関するコメント
まだコメントはありません